The Supreme Court struck down the Chevron doctrine, removing one of the foundational principles of administrative law and upending the way federal agencies rely on technical subject-matter expertise. What comes next?
Sometimes profoundly important public health opportunities are discovered by accident.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
Elizabeth Comen, a breast cancer oncologist and women’s health specialist known for her contributions in the field, has joined the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center as an associate professor of medicine.
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
Jozef Madzo was named director of bioinformatics at the Wistar Institute. He will lead and oversee Wistar’s bioinformatics projects and initiatives across a variety of advanced biomedical research programs.
Sonal Paul joined the George Washington University Cancer Center and the GW Medical Faculty Associates as a hematologist-oncologist specializing in gastrointestinal cancers.
The University of Arkansas for Medical Sciences College of Pharmacy invested Marjan Boerma, director of the UAMS College of Pharmacy Division of Radiation Health and associate director of basic science in the UAMS Winthrop P. Rockefeller Cancer Institute, in the J. Thomas May Distinguished Endowed Chair in Oncology in a June 25 ceremony.
People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.
FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC
FDA granted Fast Track designation to Syncromune Inc., a clinical-stage biopharmaceutical company, for SYNC-T SV-102 therapy, Syncromune’s lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer.
